Hi, I’ve just joined but am by no means an expert and will not pretend to be.  In any case I’ve enjoyed reading your posts.

The following excerpt is from the October 2018 Research Report prepared by the Makalu Fund:

Another important reason for the market’s current reluctance to revalue RVX is that the recent history of major Phase 3 trials of other promising drugs from other companies have failed. For example, Torectrapib, Dalcetrapib, Niacin trails were all stopped.  The market now has a show me attitude to all such tests. But the reaction to Amarin’s Phase 3 test results show that the market will immediately revalue companies if the Phase 3 results are favorable.

This trial has not ‘stopped’.  Further, one would think that the company would have, at this stage, some sense as to whether or not the Phase 3 clinical trial is moving in the right direction…..one would think (?).  3 years after commencement of the trial, major shareholders (and others?) continue to pump money into keeping the company afloat until the deed is done.  If I were company management I think the safe route would be to keep information closely held to avoid speculation and possibly having to backtrack down the road.  Just the facts please.  That said, waiting isn’t always easy.

Judging from the numbers being tossed out in your ‘contest’, it would seem that majority of you are reasonably optimistic as to how this all might ultimately pan out.  Otherwise I suppose you wouldn’t be in it.